ITIH4 and AIDS: Of the numerous clinical trials carried out so far with different HIV/AIDS vaccine candidates, only the RV144 phase III clinical trial based on priming with a recombinant canarypoxvirus ALVAC expressing the Env protein and boosting with an adjuvanted monomeric HIV-1 gp120 protein showed a modest protection of 31.2% [11].